Cargando…

The Salvinorin Analogue, Ethoxymethyl Ether Salvinorin B, Promotes Remyelination in Preclinical Models of Multiple Sclerosis

Multiple sclerosis is a neurodegenerative disease associated with demyelination and neuroinflammation in the central nervous system. There is an urgent need to develop remyelinating therapies to better treat multiple sclerosis and other demyelinating diseases. The kappa opioid receptor (KOR) has bee...

Descripción completa

Detalles Bibliográficos
Autores principales:	Paton, Kelly F., Robichon, Katharina, Templeton, Nikki, Denny, Lisa, Al Abadey, Afnan, Luo, Dan, Prisinzano, Thomas E., La Flamme, Anne C., Kivell, Bronwyn M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Neurology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8721439/ https://www.ncbi.nlm.nih.gov/pubmed/34987466 http://dx.doi.org/10.3389/fneur.2021.782190

Ejemplares similares

Evaluation of Biased and Balanced Salvinorin A Analogs in Preclinical Models of Pain
por: Paton, Kelly F., et al.
Publicado: (2020)

Nalfurafine reduces neuroinflammation and drives remyelination in models of CNS demyelinating disease
por: Denny, Lisa, et al.
Publicado: (2021)

Synthesis and κ-Opioid Receptor Activity of Furan-Substituted Salvinorin A Analogues
por: Riley, Andrew P., et al.
Publicado: (2014)

Salvinorin B methoxymethyl ether
por: Munro, Thomas A., et al.
Publicado: (2012)

Studies toward the Development of Antiproliferative Neoclerodanes from Salvinorin A
por: Vasiljevik, Tamara, et al.
Publicado: (2014)

Kappa Opioid Receptor Agonist Mesyl Sal B Attenuates Behavioral Sensitization to Cocaine with Fewer Aversive Side-Effects than Salvinorin A in Rodents
por: Kivell, Bronwyn M., et al.
Publicado: (2018)

Therapeutic Potential of Salvinorin A and Its Analogues in Various Neurological Disorders
por: Cichon, Joseph, et al.
Publicado: (2022)

Formal Total Synthesis of Salvinorin A
por: Halang, Marc, et al.
Publicado: (2022)

The Acute Effects of the Atypical Dissociative Hallucinogen Salvinorin A on Functional Connectivity in the Human Brain
por: Doss, Manoj K., et al.
Publicado: (2020)

Unusual hemiacetal structure derived from Salvinorin A
por: Carvalho, Paulo, et al.
Publicado: (2008)

Kappa Opioids, Salvinorin A and Major Depressive Disorder
por: Taylor, George T., et al.
Publicado: (2016)

Salvinorin A Does Not Affect Seizure Threshold in Mice
por: Socała, Katarzyna, et al.
Publicado: (2020)

A Protecting‐Group‐Free Synthesis of (−)‐Salvinorin A
por: Zimdars, Patrick, et al.
Publicado: (2021)

The Kappa Opioid Receptor Agonist 16-Bromo Salvinorin A Has Anti-Cocaine Effects without Significant Effects on Locomotion, Food Reward, Learning and Memory, or Anxiety and Depressive-like Behaviors
por: van de Wetering, Ross, et al.
Publicado: (2023)

Salvinorin A Inhibits Airway Hyperreactivity Induced by Ovalbumin Sensitization
por: Rossi, Antonietta, et al.
Publicado: (2017)

A Route to Potent, Selective, and Biased Salvinorin Chemical Space
por: Hill, Sarah J., et al.
Publicado: (2023)

Pharmacokinetics and Pharmacodynamics of Salvinorin A and Salvia divinorum: Clinical and Forensic Aspects
por: Brito-da-Costa, Andreia Machado, et al.
Publicado: (2021)

Salvaging Salvinorin: From Hallucinogen to Potential Therapeutic through Chemical Synthesis
por: Duvvuru, Bhawyanth, et al.
Publicado: (2023)

8-epi-Salvinorin B: crystal structure and affinity at the κ opioid receptor
por: Munro, Thomas A, et al.
Publicado: (2007)

Naltrexone but Not Ketanserin Antagonizes the Subjective, Cardiovascular, and Neuroendocrine Effects of Salvinorin-A in Humans
por: Maqueda, Ana Elda, et al.
Publicado: (2016)

The Kappa Opioid Receptor and the Sleep of Reason: Cortico-Subcortical Imbalance Following Salvinorin-A
por: Ona, Genís, et al.
Publicado: (2021)

Salvinorin A reduces mechanical allodynia and spinal neuronal hyperexcitability induced by peripheral formalin injection
por: Guida, Francesca, et al.
Publicado: (2012)

Salvinorin A decreases mortality and improves neurological outcome in a neonatal mouse hypoxia model
por: Chen, Chunhua, et al.
Publicado: (2014)

A (–)-kolavenyl diphosphate synthase catalyzes the first step of salvinorin A biosynthesis in Salvia divinorum
por: Chen, Xiaoyue, et al.
Publicado: (2017)

Solving an Old Puzzle: Elucidation and Evaluation of the Binding Mode of Salvinorin A at the Kappa Opioid Receptor
por: Puls, Kristina, et al.
Publicado: (2023)

Rapid Detection and Quantification of Hallucinogenic Salvinorin A in Commercial Salvia divinorum Products by DART-HRMS
por: Chambers, Megan I., et al.
Publicado: (2022)

Cutting-Edge Search for Safer Opioid Pain Relief: Retrospective Review of Salvinorin A and Its Analogs
por: Zjawiony, Jordan K., et al.
Publicado: (2019)

Salvinorin A inhibits ovalbumin‐stimulated allergic rhinitis and RBL‐2H3 cells degranulation
por: Shou, Qiyang, et al.
Publicado: (2021)

Sex Differences in Kappa Opioid Receptor Agonist Mediated Attenuation of Chemotherapy-Induced Neuropathic Pain in Mice
por: Paton, Kelly F., et al.
Publicado: (2022)

Studies toward bivalent κ opioids derived from salvinorin A: heteromethylation of the furan ring reduces affinity
por: Munro, Thomas A, et al.
Publicado: (2013)

Lack of effect of sublingual salvinorin A, a naturally occurring kappa opioid, in humans: a placebo-controlled trial
por: Mendelson, John E., et al.
Publicado: (2010)

Intranasal Salvinorin A Improves Long-term Neurological Function via Immunomodulation in a Mouse Ischemic Stroke Model
por: Misilimu, Dilidaer, et al.
Publicado: (2021)

Salvinorin A Administration after Global Cerebral Hypoxia/Ischemia Preserves Cerebrovascular Autoregulation via Kappa Opioid Receptor in Piglets
por: Wang, Zhenhong, et al.
Publicado: (2012)

Salvinorin A: A Mini Review of Physical and Chemical Properties Affecting Its Translation from Research to Clinical Applications in Humans
por: Orton, Edward, et al.
Publicado: (2014)

Salvinorin A, a kappa-opioid receptor agonist hallucinogen: pharmacology and potential template for novel pharmacotherapeutic agents in neuropsychiatric disorders
por: Butelman, Eduardo R., et al.
Publicado: (2015)

Salvinorin-A Induces Intense Dissociative Effects, Blocking External Sensory Perception and Modulating Interoception and Sense of Body Ownership in Humans
por: Maqueda, Ana Elda, et al.
Publicado: (2015)

Clozapine administration enhanced functional recovery after cuprizone demyelination
por: Templeton, Nikki, et al.
Publicado: (2019)

Corrigendum: Salvinorin A, a kappa-opioid receptor agonist hallucinogen: pharmacology and potential template for novel pharmacotherapeutic agents in neuropsychiatric disorders
por: Butelman, Eduardo R., et al.
Publicado: (2015)

Dynamic Strategic Bond Analysis Yields a Ten-Step Synthesis of 20-nor-Salvinorin A, a Potent κ-OR Agonist
por: Roach, Jeremy J., et al.
Publicado: (2017)

Quantitative determination of salvinorin A, a natural hallucinogen with abuse liability, in Internet-available Salvia divinorum and endemic species of Salvia in Taiwan
por: Lin, Po-Xiang, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_t1jfamvipjd0k9vcbllksen9nc